Print this page    •   Back to Web version of article

Approval of Zerit XR, a New Formulation That Allows Once-a-Day Dosing

December 31, 2002

Today the Food and Drug Administration approved a new, extended release formulation of Zerit (stavudine, d4T) called Zerit XR. This extended-release formulation has been demonstrated to maintain measurable plasma concentrations for 24 hours after once-daily dosing. Zerit XR is indicated for the treatment of HIV in combination with other antiretrovirals. The recommended dose of Zerit XR is 100 mg once daily for individuals weighing at least 60 kg and 75 mg once daily for individuals weighing less than 60 kg.

In a clinical study conducted in 783 treatment-na•ve, HIV-infected individuals Zerit® XR was comparable to the previously approved twice daily formulation of Zerit. In this randomized, controlled study, participants were randomized to either the extended release or standard formulation, in combination with lamivudine and efavirenz. The proportion of patients with HIV-RNA (viral load levels) below 400 copies/mL at 48 weeks was 79% and 76% for the extended release and immediate release-containing regimens, respectively. For viral load under 50, the response rates were 55% and 57% for the new and old formulations, respectively. The tolerability and safety profile of the new once daily, extended release formulation is comparable to that of the previously approved twice daily formulation.

The study results were supported by a second, smaller study in 150 treatment na•ve patients.

More convenient formulations, such as Zerit XR, may help patients with HIV more readily adhere to treatment regimens.

The full label will soon be available at the FDA Web site. Simply click "Z" in the index, and scroll to look for Zerit XR.

Zerit XR is a product of the Bristol-Myers Squibb Company.




This article was provided by U.S. Food and Drug Administration. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art13952.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.